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Introduction
Acute gout, also called podagra when it aﬀ ects the ﬁ rst 
metatarsophalangeal joint, is due to the inﬂ ammatory 
reaction of joint tissues when monosodium urate (MSU) 
crystals form within the joint. Th e link between crystal 
deposition and joint inﬂ ammation was made by Garrod, 
who developed the thread-test assay of serum urate and 
stated that ‘the deposited urate of soda may be looked 
upon as the cause, and not the eﬀ ect, of the gouty 
inﬂ ammation’. Older clinical descriptions of acute gout, 
from Hippocrates to Charcot, detailed the very sudden 
and inﬂ ammatory character of an attack.
Th e initial symptoms of a gouty attack are 
sudden and violent, taking place nearly always at 
night. Th e patient feels a sudden onset of pain … 
it often aﬀ ects the big toe 1st MT joint, which 
becomes rapidly red and swollen; the veins of the 
leg can become dilated, and the leg can become 
purple and sometimes accompanied by bruising.
Charcot, Maladies des Vieillards, 1890
Th is account brings to life all of the cardinal manifes-
tations of acute inﬂ ammation. After McCarty and 
Hollander published their observations that the crystals 
found in the synovial ﬂ uid were composed of MSU [1], 
there remained no doubt that urate crystals are the cause 
of this intense inﬂ ammation. Th ese observations have led 
to detailed analyses of the inﬂ ammatory pathways 
triggered by urate crystals and the mechanisms that link 
crystal deposition to tissue inﬂ ammation.
During the past decade, the role of innate immune 
responses in the initiation of inﬂ ammatory and immune 
responses to injury and infection has gained prominence. 
In contrast to the acquired immune system, innate 
responses orchestrate the immediate and early phases of 
host defence to microbes as well as to injury, initiating the 
inﬂ ammatory reaction and recruiting cells of the acquired 
immune system to the site of inﬂ ammation. Th ese 
advances bring our attention back to the interplay between 
cells of the innate immune system and the products of 
tissue damage and cell death – the so-called danger signals 
or danger-associated molecular patterns. MSU represents 
one of these signals that activate cellular defences. In the 
present review, we cover the recent develop ments in our 
under standing of MSU’s eﬀ ects, integrating this infor-
mation with previous knowledge regarding the inﬂ am-
matory response provoked by urate crystals.
Crystal factors
MSU crystallizes when its plasma concentration exceeds 
its solubility (around 7  mg/dl, or 420  μmol/l). Concen-
tration may not be the only determinant, however, and 
other factors have been reported to aﬀ ect urate solubility. 
We know from clinical observation that patients with 
hyperuricaemia can be asymptomatic, sometimes for 
long periods before the ﬁ rst declaration of gout, so there 
must be modifying factors present in biological ﬂ uids 
that aﬀ ect urate solubility and their capacity to form 
crystals. Furthermore, patients can have known MSU 
deposits that are clinically quiescent – indicating that 
there is further regulation at the level of the tissue 
response to urate (see later).
Th e factor or factors predisposing certain hyper-
uricaemic persons and not others to develop gout are as 
yet unknown. In vitro, several factors have been described 
to inﬂ uence urate solubility, including pH, temperature, 
ionic strength and the binding of urate to plasma 
macromolecules [2]. Katz and Schubert suggested that 
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proteoglycans of connective tissue origin can increase 
urate solubility. Th eir experiments showed that increas-
ing the concentration of a cartilage protein polysac-
charide extract increased urate solubility threefold, from 
6 to 17  mg/100  ml. How this may explain the site of 
deposition of urate crystals in vivo, however, is not yet 
clear [3]. Not only is the solubility of urate inﬂ uenced by 
its binding to plasma proteins, but also its inﬂ ammatory 
potential. Crystals coated with IgG fragments were more 
inﬂ ammatory than naked crystals [4,5]. As inﬂ ammation 
subsides, apolipoprotein B displaces the IgG by competi-
tively coating sites on crystals and could contri bute in 
part to the resolution of acute gouty arthritis [6].
Th ese ﬁ ndings indicate that crystal-bound proteins 
modify the cellular response, but the underlying mecha-
nisms of these eﬀ ects remain to be elucidated. As crystals 
are essentially foreign bodies, they have toxic eﬀ ects on 
cells (see below). Surprisingly, the size of MSU crystals 
does not seem to be a major determinant of its inﬂ am-
matory potential, as varying the mean crystal size 
between 2.0 and 11.8 μm did not aﬀ ect TNF production 
by monocyte/macrophage cells [7].
Cell types
Th e cells most studied in gouty inﬂ ammation are leuco-
cytes – in particular, neutrophils and macrophages. 
Addition of MSU crystals to neutrophils results in cell 
death and release of lysosomal and cytoplasmic enzymes. 
In vitro studies showed that when native crystals were 
added to neutrophil preparations, ingested crystals 
induced the release of lysosomal contents by rupturing 
lysosomal membranes [8]. Th is pathway of cell death 
appears to be abrogated when crystals are coated with 
immunoglobulin, but release of lysosomal enzymes still 
took place [9]. Th e importance of neutrophils in the acute 
response is further supported by the eﬀ ectiveness of 
colchicine, a potent inhibitor of neutrophil lysosomes as 
well as cell migration [10].
Neutrophils are attracted to the site of inﬂ ammation by 
chemotactic factors as well as cytokines and chemokines 
(see later) that act upon endothelial adhesion and 
transmigration. Among the factors known to be 
upregulated during gouty inﬂ ammation are IL-1β, IL-8, 
CXCL1 and granulocyte colony-stimulating factor [11].
Th e interactions between monocyte/macrophages with 
MSU do not appear to be so deadly, eliciting principally 
the secretion of proinﬂ ammatory cytokines. Both IL-1β 
and TNFα were secreted when monocytes were cultured 
in the presence of crystals,  and their eﬀ ects on cell 
proliferation were inhibited by speciﬁ c blocking anti-
bodies [12,13]. Macrophages do not appear to respond as 
well to MSU as to monocytes. When macrophages were 
diﬀ erentiated in vitro, they became less proinﬂ am matory 
in their response to MSU crystals, even though they 
retained their capacity for phagocytosis [7]. In a subse-
quent study by the same group, a potential role of trans-
forming growth factor beta was suggested to account for 
this phenomenon [14]. Th e autoregulation of inﬂ amma-
tion by phagocytes may explain the self-limiting nature of 
acute gout, as well as the fact that the presence of MSU 
crystals in a joint is not always accompanied by inﬂ am-
matory signs and symptoms. Th e diﬀ erence in the cellular 
response seems to be linked to the state of the macro-
phage, and as our understanding of the phenotypic 
variations of macrophages evolves, including the concept 
of M1 and M2 macrophages, we may gain a better under-
standing on how this impacts on inﬂ ammation. Of 
particular interest is the role of resident macrophages, as 
they have been reported to play a primordial part in 
initiating the tissue response to MSU in a mouse 
peritonitis model [15].
Among the other cell types that may participate in 
gouty inﬂ ammation, mast cells deserve a mention. In the 
air pouch model of gout, the density of mast cells 
increased in the lining layer rapidly after crystals were 
injected, and was correlated with the histamine content 
of the pouch liquid [16]. Using a microarray approach to 
analyse gene expression by lining cells of the air pouch, it 
was interesting to observe that the gene encoding histi-
dine decarboxylase, the enzyme that synthesizes hista-
mine, is rapidly upregulated after injection of MSU 
crystals [17]. In the peritonitis model of gout, depletion 
of peritoneal mast cells attenuated the neutrophil 
inﬂ ammatory response [18]. Finally, mast cells are able to 
release IL-1β on activation of the NALP3 inﬂ ammasome 
through lipopolysaccharide [4], but we have no 
information on whether MSU can also perform this 
function. Th ese results suggest that mast cells participate 
in the acute response of tissue to MSU crystals and 
contribute to neutrophil recruitment.
IL-1 as a crucial mediator of gouty infl ammation
Proinﬂ ammatory cytokines undoubtedly have a critical 
role in orchestrating the inﬂ ammatory reaction to MSU 
crystals. Recent attention has focused particularly on the 
role of IL-1. In murine models of crystal-induced inﬂ am-
mation, the injection of MSU into a preformed air pouch 
or within the peritoneal cavity elicited an inﬂ ux of 
neutrophils that was accompanied by the local accumu-
lation of chemoattractants and cytokines. Although care 
needs to be taken when extrapolating ﬁ ndings from these 
models to joint inﬂ ammation in gout, both the air pouch 
and the peritoneum have a lining that is morphologically 
similar to the synovium, and both models reconstitute 
the complex interplay that occurs between resident and 
inﬁ ltrating immune cells.
Experimental data from crystal-induced peritonitis, 
crystal-induced air pouch inﬂ ammation or urate crystals 
Busso and So Arthritis Research & Therapy 2010, 12:206 
http://arthritis-research.com/content/12/2/206
Page 2 of 8
injected intra-articularly provide compelling evidence for 
the role of IL-1 in the pain and inﬂ ammation associated 
with gout. Two lines of study have been employed – a 
murine IL-1R1 knockout model, and the eﬀ ects of IL-1 
blockade (by antibodies against IL-1β, IL-1RΑ or by 
mIL-1 Trap). Th ese inhibitors of IL-1 were as eﬀ ective as 
genetic deletion of IL-1R1 in reducing inﬂ ammation and 
hyperalgesia in these murine models [11,19,20]. Further-
more, the rapid clinical response of patients with acute 
gouty arthritis to IL-1 inhibition by a variety of agents 
(IL-1RA, IL-1Trap or an anti-IL-1β monoclonal antibody) 
validates the concept that this cytokine plays a key role in 
gouty inﬂ ammation [20-22].
Th e cellular target of IL-1β released by MSU crystals 
in the peritonitis model does not appear to be 
leucocytes. Using bone-marrow chimeras, Chen and 
colleagues demonstrated that MSU-induced inﬂ am-
mation was not modiﬁ ed when normal wild-type mice 
received IL-1RI–/– or MyD88–/– bone marrow, but 
inﬂ ammation was attenuated when IL-1RI-deﬁ cient or 
MyD88-deﬁ cient mice received normal bone marrow 
[19]. As both IL-1RI and MyD88 are essential for signal 
transduction on IL-1 binding, these results showed that 
nonhematopoieitic cells, most probably endothelial 
cells, are necessary to develop fully the inﬂ ammatory 
response to IL-1β.
Role of NLRP3 (NALP3) infl ammasome in gout
IL-1β is the prototypic inﬂ ammatory cytokine and has 
multiple actions on cells and tissues (reviewed in [23]). 
Th e cytokine is produced as an inactive pro-molecule by 
immune cells such as macrophages, monocytes and 
dendritic cells, and is then cleaved into the active p17 
form of IL-1β to be secreted out of the cell. Cleavage of 
pro-IL-1β is catalysed by caspase-1 (also known as IL-1-
converting enzyme). Caspase-1 is a member of the family 
of inﬂ ammatory caspases that include caspase-4, 
caspase-5, caspase-11 and caspase-12; in the context of 
IL-1β processing, caspase-1 accounts for the major 
activity that requires the formation of a molecular 
platform known as the inﬂ ammasome (reviewed in [24]). 
Other pathways of IL-1β processing independent of 
caspase-1 have been described, implicating neutrophil-
derived and mast cell-derived proteases [25,26].
Th e inﬂ ammasome is a cytoplasmic protein complex 
composed of a protein of the NLRP (or NALP) family, an 
adapter ASC protein as well as an inﬂ ammatory caspase. 
Fourteen NLRPs have been identiﬁ ed in humans, and 
they all have multiple domains that share common 
features. Th e ASC adapter contains a PYD domain that 
mediates interaction with a homologous domain on 
NLRP, as well as a CARD domain that interacts with 
caspase-1. For the NLRP3 inﬂ ammasome, a second 
adapter – the Cardinal protein – is needed to recruit a 
second molecule of caspase-1, so as to form a dimer with 
the caspase-1 recruited by ASC (Figure 1). Numerous 
danger-asso cia ted molecular patterns and pathogen 
associated molecular patterns have been reported to 
signal via the NLRP3 inﬂ ammasome, including bacterial 
cell wall components, bacterial RNA or bacteria 
themselves, such as Listeria monocytogenes or Staphylo-
coccus aureus. In addition, NLRP3 can be activated by 
signals that induce potassium eﬄ  ux, such as ATP, via the 
P2X7 receptor, or by toxins such as nigericin.
Th e group of Tschopp discovered that many inorganic 
particles, including MSU and calcium pyrophosphate 
dihydrate crystals, are capable of activating the NLRP3 
inﬂ ammasome to process and secrete active IL-1β as well 
as IL-18 [27,28]. Th e list of NRLP3 triggers is currently 
ever expanding, and includes alum, hemozoin and DNA 
[29-31]. Macrophages deﬁ cient for components of the 
NLRP3 inﬂ ammasome were unable to secrete active IL-
1β following stimulation with MSU and calcium 
pyrophosphate dihydrate crystals. Moreover, MSU-
induced peritonitis was decreased in ASC-deﬁ cient or 
caspase-1-deﬁ cient mice. Colchicine, a drug commonly 
used in the treatment of acute gout, was found to block 
IL-1β maturation, probably by inﬂ uencing crystal 
endocytosis and/or presentation of crystals to the 
inﬂ ammasome. Th e results show that MSU crystals 
initiate an inﬂ ammatory cascade, the starting point being 
the release of active IL-1β from monocytes and 
macrophages. Th ese ﬁ ndings, however, also raise 
questions about the steps that connect cellular contact 
with crystals with inﬂ ammasome activa tion, processes 
that are still not completely understood. It may involve 
general mechanisms shared by other inﬂ ammasome 
activators, such as potassium eﬄ  ux that is regulated by 
K+ channels like P2X7, or by the sensing of reactive 
oxygen species that are released during cell stress.
Other cytokines
Besides IL-1β, both IL-6 and TNFα are also upregulated 
when monocytes are in contact with MSU in vitro and 
with gouty tissues in vivo [11]. Although there is clear 
evidence that TNF is released at the site of inﬂ ammation 
in animal models, there has not been any systematic 
study into the eﬀ ects of interfering with the TNF 
signalling pathway in gout. Unpublished data obtained by 
the authors showed that TNF blockade with an anti-
TNFα antibody did not block neutrophil inﬂ ux in the 
peritonitis model, arguing against a major role for TNF; 
but there are anecdotal data of chronic gout that 
responded to anti-TNF therapy in patients [32-34]. Th e 
role of IL-6 is even less clear, although its known 
proinﬂ ammatory properties on the acute phase response 
and on leucocytes and endothelium would suggest a role 
in amplifying inﬂ ammation.
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Th ere is a growing body of data showing that chemo-
kines also play a central role in acute gouty inﬂ ammation, 
particularly in neutrophil recruitment. IL-8 (CXCL8) and 
closely related chemokines, such as GROα (CXCL1), bind 
to the receptor CXCR2 to promote neutrophil chemo taxis 
and can also aﬀ ect angiogenesis. In this context, acute 
MSU crystal-induced neutrophilic inﬂ ammation (4 hours 
after crystal injection into a subcutaneous air pouch) was 
completely dependent on chemokine ligands of CXCR2 in 
mice, as demonstrated in experiments using CXCR2 
knockout mice [35]. A role for IL-8 was also conﬁ rmed by 
neutralizing IL-8 with an antibody in a rabbit model of 
MSU-induced arthritis, resulting in inhibition of the 
delayed phase of neutrophil inﬂ ux at 24 hours [36].
Th e evidence of a role for these and other cytokines is 
summarized in Table 1.
Toll-like receptors in gout: are they important?
Toll-like receptors (TLRs) are pivotal sensors of infec-
tious and danger signals on leucocytes, and are an 
integral part of the innate immune system [38] – and 
their role in the pathogenesis of inﬂ ammatory diseases 
has become increasingly clear [39]. MSU crystals may be 
a danger signal released from injured cells that trigger 
innate immune responses via TLRs, but the experimental 
evidence available to date provides no clear answer.
Using knockout mice in models of crystal-induced 
inﬂ ammation, macrophages from TLR2 and TLR4 knock-
out mice showed decreased expression of inﬂ ammatory 
cytokines such as IL-1β, TNFα and transforming growth 
factor beta-1 on exposure to MSU [40]. Furthermore, 
CD14 – an adaptor molecule that is shared by TLR2 and 
TLR4 to promote inﬂ ammatory signalling – appears to 
be an important component of the inﬂ ammatory 
response both in vitro and in vivo. Bone-marrow-derived 
macrophages from CD14 knockout mice showed reduced 
secretion of IL-1β in response to MSU, and leucocyte 
inﬂ ux was reduced in the air pouch model in these same 
mice [41]. Th ese experiments also suggest that the phago-
cytosis phase of the inﬂ ammatory response can be 
dissociated from the responder phase, when pro-
inﬂ ammatory cytokines are produced and secreted. Th e 
absence of TLR2 or TLR4 reduced phagocytotic uptake 
as well as inﬂ ammation, but deﬁ ciency of CD14 reduced 
the production of IL-1β without any eﬀ ect of crystal 
phagocytosis.
Figure 1. Composition of the NALP3 infl ammasome and its activation by monosodium urate. Phagocytosis of monosodium urate 
(MSU) crystals leads to the generation of reactive oxygen species (ROS) through activation of NADPH oxidases. This event activates the NLRP3 
infl ammasome. MSU crystals may also induce the secretion of ATP, which in turn activates P2X7R. On activation of the P2X7 receptor, there is rapid 
exit of intracellular potassium that triggers the NLRP3 infl ammasome. A rise in intracellular calcium is also required for the secretion of processed 
IL-1β. The macromolecular complex (infl ammasome) consists of NLRP3, ASC and procaspase-1, and CARDINAL. Assembly leads to activation of 
caspase-1, which in turn cleaves pro-IL-1β to produce biologically active IL-1β. ASC, apoptosis-associated speck-like protein containing a caspase 
recruitment domain (CARD); FIIND, domain with function to fi nd; LRR, leucine-rich repeat; MDP, muramyl dipeptide; NACHT, domain conserved in 
NAIP, CIITA, HET-E and TP1; NALP3, NACHT-containing, LRR-containing and PYD-containing protein; PYD, pyrin death domain.
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Th e ﬁ ndings in favour of a role for TLRs, however, are 
put into question by results from another group. Using 
the peritonitis model, Chen and colleagues found that 
none of the nine TLR-deﬁ cient mouse strains available 
showed an impairment in neutrophil inﬂ ux. To exclude 
the role of TLR5 or TLR8 (mice deﬁ cient in these TLRs 
are not available), transfectants were generated with all 
the known TLRs and the NF-κB response to MSU was 
measured. None of the 11 TLRs tested responded to 
MSU stimulation. Although these ﬁ ndings do not exclude 
a role for an unidentiﬁ ed co-receptor that may cooperate 
with TLRs, they strongly suggest that TLRs do not 
recognize MSU or calcium pyrophosphate dihydrate 
crystals and that TLR2 and TLR4 may not be crucial for 
MSU-induced inﬂ ammation as previously suggested [19].
Why these two sets of results are so diﬀ erent is still not 
understood, but one can invoke possibly diﬀ erent types 
of resident cells in the two models that have diﬀ erential 
requirements for activation, or perhaps local modifying 
factors (such as proteins).
Events inﬂ uencing the early phase of innate immune 
response in gouty inﬂ ammation include expression of the 
triggering receptor expressed on myeloid cells-1 
(TREM-1). Th is molecule is a member of a family of 
surface receptors that act to amplify innate responses in 
infectious and inﬂ ammatory states [42]. TREM-1 expres-
sion was by murine resident peritoneal macrophage s, and 
inﬁ ltrating leucocytes were upregulated in the murine air 
pouch model of crystal-induced inﬂ ammation [17]. 
Interestingly, co-stimulation of resident peritoneal 
macrophages with MSU crystals and an anti-TREM-1 
agonist antibody synergistically increased the production 
of both IL-1β and monocyte chemoattractant protein-1 
compared with stimulation with crystals alone [43]. Little 
is known to date about the ligands that activate TREM-1, 
but TREM-1 blockade appears to attenuate inﬂ ammation 
in animal models.
Complement and soluble mediators of 
infl ammation
MSU crystals also promote inﬂ ammation by indirect 
eﬀ ects on activation of inﬂ ammatory cells, as exempliﬁ ed 
by MSU crystal-induced activation of the classical 
pathway of complement in vitro [44]. Th is classical com-
plement activation process does not require immuno-
globulin, but is ampliﬁ ed by both C-reactive protein and 
IgG [45]. MSU crystals also activate the alternative 
pathway in vitro [46] and, in this process, direct cleavage 
of C5 to C5a and C5b is triggered by the formation of a 
stable C5 convertase on the MSU crystal surface [47].
Th e formation of leucotrienes and arachidonic acid 
metabolites induced by MSU has been extensively 
studied in the past, and is largely accounted for by the 
eﬀ ects of MSU crystals on neutrophils and platelets 
recruited to the inﬂ ammatory site [48,49]. Pretreatment 
of animals with a nonsteroidal anti-inﬂ ammatory drug 
blocked the generation of inﬂ ammatory prosta glandins 
and exudate formation, but did not inhibit local 
neutrophil accumulation [50].
Unresolved questions
Although our understanding of how MSU crystals trigger 
inﬂ ammation has advanced considerably in the past 20 
years, a number of fundamental and clinically relevant 
questions remain unanswered.
Th e ﬁ rst and foremost question concerns the exact 
mecha nisms that lead to spontaneous resolution of 
inﬂ am mation in gout. We have already discussed the 
possible role of transforming growth factor beta secretion 
by mature macrophages, but is it possible that the 
Table 1. Cytokine and chemokines that play a role in gouty infl ammation
 Actions contributing to gouty
Cytokine infl ammation Produced by References
IL-1β Endothelial adhesion Monocyte, dendritic cells infl ammatory  [11,12,20,25]
  macrophage
 Endogenous pyrogen
TNFα Cellular activation Monocyte, macrophage, lining cell [11,12]
 Endothelial adhesion
 Phagocytosis
IL-6 ? Monocyte, macrophage [11,17]
Granulocyte colony-stimulating factor Neutrophil survival and proliferation Endothelium, macrophage [11,17]
CXCL1 (KC, Groα) Neutrophil chemotaxis Macrophage, neutrophil [11]
CXCL8 (IL-8) Neutrophil chemotaxis Macrophage, endothelium [36,37]
CCL2 (monocyte chemoattractant protein-1) Monocyte and dendritic cell chemotaxis  [11]
 Mast cell degranulation  
CCL3 (macrophage infl ammatory protein-1) Neutrophil chemotaxis Monocyte, macrophage [11]
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inﬂ am matory response of phagocytes to MSU may 
require multiple signals beyond those that are already 
men tioned? In in vitro experiments, triggering of the 
inﬂ amma some to process IL-1β is a multistep process. In 
the absence of a ﬁ rst signal that induces production of 
pro-IL-1β, such as phorbol myristate acetate or ultrapure 
lipopolysaccharide, monocytes/macrophages do not 
spontaneously secrete mature IL-1β when cultured with 
MSU crystals (personal observation). Is it possible that 
such a ﬁ rst signal is also required in man? If this is the 
case, what may it be in the clinical situation? Could 
remission be related to the removal of such a ﬁ rst signal?
A second question that has vexed researchers in this 
ﬁ eld concerns the explanation for why crystals are not 
always inﬂ ammatory. In part, this could be linked to the 
mechanisms evoked in the paragraph above, but another 
possible explanation is the surface modiﬁ cation of 
crystals by proteins and other agents that may modify 
their phlogistic potential. A body of research from the 
1990s showed that protein coating modiﬁ ed crystal-
induced inﬂ ammation – but how does this work, and 
how do we integrate this with the more recent data on 
NLRP3 activation?
Finally, a mechanism to explain why urate-lowering 
therapies provoke acute ﬂ ares needs to be found. Th is is a 
common clinical problem that may lead patients to 
abandon urate-lowering therapies. Although the strategy 
for prevention of gout ﬂ ares is straightforward, a better 
understanding of its cause(s) will lead to more eﬀ ective 
prevention.
Conclusion
Gout is a paradigm for acute sterile inﬂ ammation that is 
triggered by interactions between MSU microcrystals 
and the local tissue environment. Our current under-
standing suggests that resident cells with such tissues, 
such as resident macrophages or monocytes, react to 
crystal deposition by uptake of crystals through phago-
cytosis. Th rough a series of steps that are still not well 
understood, these phagocytes activate the NLRP3 inﬂ am-
masome, resulting in processing and secretion of IL-1β. 
Th e subsequent recruitment of inﬂ ammatory leucocytes 
to the site, mediated most probably by endothelial 
activation, can account for the subsequent release of 
inﬂ ammatory mediators and the recognized inﬂ amma-
tory manifestations of acute gout (Figure 2). Although 
multiple cytokines and chemokines are involved in the 
inﬂ ammatory process, there is a suggestion that these are 
produced in a hierarchical manner, secondary to IL-1β 
release. Th e understanding of these mechanisms oﬀ ers us 
Figure 2. Multiple steps are needed to trigger infl ammation in gout. (1) Recognition of monosodium urate (MSU) crystals by components 
of the innate immune system – Toll-like receptor (TLR) 2/TLR4, triggering receptor expressed on myeloid cells (TREM), and so forth. (2) Uptake of 
MSU by phagocytotic cells (for example, macrophages and eventually mast cells). (3) Activation of the NALP3 infl ammasome by MSU (see details 
in Figure 1). (4) Release of IL-1β from the cell. (5) Endothelial IL-1β receptor type 1 (IL-1R) activation. (6) Proinfl ammatory mediators, including IL-8, 
release a potent chemokine for neutrophil recruitment. (7) Neutrophil recruitment into the site of infl ammation. (8) Release of proinfl ammatory 
compounds by neutrophils, including more IL-1β.
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a novel opportunity to interfere with this inﬂ ammatory 
pathway, and may one day develop more eﬀ ective 
therapies for gout.
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